Invitae Corp at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 12:00PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst

Hey, everyone. Good morning. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst here at Morgan Stanley. It's my pleasure to host Ken Knight, CEO of Invitae here. And again, thanks for joining us. Before we get started, I just have to read the research disclosures. For important disclosures, please see the Morgan Stanley website at morganstanley.com/researchdisclosures. If you have any questions, please reach out to your sales rep.

Questions and Answers:

Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst

So with that, Ken, thanks again for joining us. Maybe just to set the stage, I mean, obviously, it's been a very eventful year for Invitae. Can you talk about sort of your key priorities heading into year-end and into '23 after the restructuring? And what are you most looking forward to over the next 12 months?

Kenneth D. Knight - Invitae Corporation - President, CEO & Director

Well,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot